Cognitive Impairment After Stroke and Treatment With Fluoxetine: A Planned Analysis of the AFFINITY Randomized Controlled Trial

Am J Geriatr Psychiatry. 2022 Dec;30(12):1351-1352. doi: 10.1016/j.jagp.2022.08.002. Epub 2022 Aug 20.

Authors

Osvaldo P Almeida¹, Graeme J Hankey², Andrew Ford², Christopher Etherton-Beer², Leon Flicker², Maree L Hackett³; AFFINITY Trial Collaboration

Affiliations

¹ Medical School, University of Western Australia, Perth, Australia. Electronic address: osvaldo.almeida@uwa.edu.au.
² Medical School, University of Western Australia, Perth, Australia.
³ The George Institute for Global Health, Faculty of Medicine, the University of New South Wales, Australia.

PMID: 36115731
DOI: 10.1016/j.jagp.2022.08.002

No abstract available

Publication types

Randomized Controlled Trial
Letter

MeSH terms

Cognitive Dysfunction* / drug therapy
Cognitive Dysfunction* / etiology
Double-Blind Method
Fluoxetine / adverse effects
Humans
Selective Serotonin Reuptake Inhibitors / adverse effects
Stroke* / complications
Stroke* / drug therapy
Treatment Outcome

Substances

Fluoxetine
Serotonin Uptake Inhibitors